Ardent Health Partners, Inc. (ARDT)vsAstraZeneca PLC (AZN)
ARDT
Ardent Health Partners, Inc.
$8.68
+0.93%
HEALTHCARE · Cap: $1.32B
AZN
AstraZeneca PLC
$185.95
-0.83%
HEALTHCARE · Cap: $282.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 840% more annual revenue ($60.44B vs $6.43B). AZN leads profitability with a 17.2% profit margin vs 2.1%. ARDT trades at a lower P/E of 9.7x. AZN earns a higher WallStSmart Score of 64/100 (C+).
ARDT
Hold49
out of 100
Grade: D+
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARDT.
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of 7.7% — below average capital efficiency
2.1% margin — thin
Earnings declined 3.4%
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ARDT
The strongest argument for ARDT centers on P/E Ratio, Price/Book.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ARDT
The primary concerns for ARDT are Market Cap, Return on Equity, Profit Margin. Thin 2.1% margins leave little buffer for downturns.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
ARDT profiles as a value stock while AZN is a mature play — different risk/reward profiles.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 49/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ardent Health Partners, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Ardent Health Partners, Inc., based in Nashville, Tennessee, is a leading healthcare organization committed to providing exceptional, patient-centered care via its robust network of hospitals and outpatient facilities. With a reputation for innovation and quality, Ardent boasts a diverse portfolio of acute care hospitals and is focused on developing healthcare solutions that address the unique needs of the communities it serves. Supported by a strong financial foundation and a strategic growth plan, the company is strategically positioned to expand healthcare access and enhance patient outcomes in an ever-evolving industry landscape.
Visit Website →AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?